Tesamorelin vs Sermorelin: Research Peptide Comparison

Tesamorelin and sermorelin are both GHRH analogues, which makes them a natural pair to compare. This article sets out how they differ — in sequence basis, structure and the research areas each appears in — and how each is handled as laboratory material. It is a comparison rather than a pair of profiles; for full background, follow the links to each compound’s guide.

Everything here is factual and educational. It is not guidance for the use of any material in humans or animals, and it makes no claim about safety, performance or outcomes. For the wider class, see Growth Hormone Secretagogue Research Peptides.

The table below summarises the factual points of difference.

Both peptides act at the GHRH receptor, so the difference is one of sequence rather than receptor. Sermorelin is the native GHRH(1-29) fragment — the shortest portion that retains the hormone’s receptor activity — and serves as the unmodified reference for the family. Tesamorelin keeps the longer GHRH(1-44) sequence and adds an N-terminal modification for stability. These are descriptions of structure studied in the laboratory, not statements about any effect. The detail is in the tesamorelin research overview and the sermorelin research overview.

The contrast is length and modification. Sermorelin is the minimal 1-29 fragment, unmodified; tesamorelin is the full 1-44 sequence with a terminal modification layered on. Holding the two side by side separates the contribution of length from the contribution of the modification — which is part of why the native fragment is a useful baseline. For the notation used in a sequence description, see Understanding Peptide Sequence Notation.

Both appear in GHRH-receptor research, and the descriptions here summarise where each is studied rather than any established result. Sermorelin features as the native reference sequence; tesamorelin features where the effect of length and terminal modification is part of the question. These are areas of published study, not recommended uses.

Both are supplied as lyophilised peptides and handled the same way: confirm the material against its specification on receipt, keep it in the stated storage conditions, and maintain clear records. See Tesamorelin Storage & Handling, Sermorelin Storage & Handling and the general Peptide Storage Guidelines.

Because both act at the same receptor, the choice follows the design question: a native, unmodified baseline points toward sermorelin, while a longer, modified analogue points toward tesamorelin. Neither framing implies one is superior. Both sit within the class covered in Growth Hormone Secretagogue Research Peptides.

Both peptides are available in the catalogue with full specifications and storage information: Tesamorelin and Sermorelin. The complete range is in the research catalogue, and our approach to material consistency is on the Quality page.

For laboratory research use only. Not for human or animal consumption. The material on this page is educational and factual: it compares how two research compounds are described in published study and handled in the laboratory. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance or outcomes. Where a product specification is provided with a material, that document is the definitive reference and takes precedence over any general information given here.